Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 3:15 PM
Ignite Modification Date:
2025-12-25 @ 1:37 PM
NCT ID:
NCT03405792
Pre Assignment Details:
Four to 6 weeks post- chemoradiation, patients began monthly cycles of adjuvant TMZ (minimum 6 and maximum 12 cycles of adjuvant TMZ) and treatment with Optune. Patients began treatment with pembrolizumab no sooner than 3 weeks after starting Optune therapy.
Forty participants were consented. Nine were deemed ineligible. Five who were eligible to participate withdrew or were withdrawn because they did not start or discontinued Optune or did not receive pembrolizumab.
Recruitment Details:
Recruitment began in 2018 and lasted until July 2021. Patients with newly diagnosed GBM who completed standard of care radiation therapy together with concomitant TMZ were recruited. Neuro-oncologists identified subjects as part of routine clinical care. Patients with newly-diagnosed GBM who underwent maximal safe resection followed by chemoradiation consisting of concomitant TMZ 75mg/m2 daily and RT with minimal RT dose of 40gy were eligible for this trial.
Study:
NCT03405792
Study Brief:
Results Section:
NCT03405792